Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 18;8(10):e76882.
doi: 10.1371/journal.pone.0076882. eCollection 2013.

Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database

Nicole Kubitz  1 , Maneesha Mehra, Ravi C Potluri, Nitesh Garg, Nicole Cossrow
Affiliations

Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database

Nicole Kubitz et al. PLoS One. .

Abstract

Context: Treatment Resistant Depression (TRD) is a significant and burdensome health concern.

Objective: To characterize, compare and understand the difference between TRD and non-TRD patients and episodes in respect of their episode duration, treatment patterns and healthcare resource utilization.

Design and setting: Patients between 18 and 64 years with a new diagnosis of major depressive disorder (MDD) and without a previous or comorbid diagnosis of schizophrenia or bipolar disease were included from PharMetrics Integrated Database, a claims database of commercial insurers in the US. Episodes of these patients in which there were at least two distinct failed regimens involving antidepressants and antipsychotics were classified as TRD.

Patients: 82,742 MDD patients were included in the analysis; of these patients, 125,172 episodes were identified (47,654 of these were drug-treated episodes).

Main outcome measures: Comparison between TRD and non-TRD episodes in terms of their duration, number and duration of lines of treatment, comorbidities, and medical resource utilization.

Results: Of the treated episodes, 6.6% (N = 3,134) met the criteria for TRD. The median time to an episode becoming TRD was approximately one year. The mean duration of a TRD episode was 1,004 days (vs. 452 days for a non-TRD episode). More than 75% of TRD episodes had at least four lines of therapy; half of the treatment regimens included a combination of drugs. Average hospitalization costs were higher for TRD than non-TRD episodes: $6,464 vs. $1,734, as were all other health care utilization costs.

Conclusions: While this study was limited to relatively young and commercially covered patients, used a rigorous definition of TRD and did not analyze for cause or consequence, the results highlight high unmet medical need and burden of TRD on patients and health care resources.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Dr. Kubitz is an employee of Janssen-Cilag GmbH, Ms.Mehra is an employee of Janssen Global Services and Dr. Cossrow was an employee of Janssen Global Services at the time of the data analysis and manuscript development. Mr. Potluri and Mr. Garg are employees of SmartAnalyst Inc, which was contracted by Janssen to carry out the data analysis as well as contribute to manuscript development. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Patient selection flow.
Cascade depicting patient selection after applying various filters, and the number of patients excluded at each filter.
Figure 2
Figure 2. Distribution of episodes based on lines of therapy.
Distribution of episodes by number of lines of treatment contained therein, compared for TRD and non-TRD episodes.
See this image and copyright information in PMC

References

    1. Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, et al. (2011) Cross-national epidemiology of DSM-IV major depressive episode. BMC Med 9: 90. - PMC - PubMed
    1. OECD Expert Meeting: Mental health, disability and work (2010) Available: http://www.oecd.org/els/45008308.pdf Accessed 2013 Sep 9.
    1. Hirschfeld RMA, Weissman MM (2002) Risk Factors For Major Depression And Bipolar Disorder. Neuropsychopharmacology: The Fifth Generation of Progress Section 8: Chapter 70.
    1. French L Treatment of Co-morbid Alcohol Use Disorders and Depression, Baylor College of Medicine, Houston, Texas, Available: http://www.bcm.edu/psychiatry/index.cfm?pmid=20058 Accessed 2013 Sep 9.
    1. Musselman DL, Evans DL, Nemeroff CB (1998) The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 55: 580–592. - PubMed

Publication types

MeSH terms